457 related articles for article (PubMed ID: 12388858)
1. Implementation of the 3Rs (refinement, reduction, and replacement): validation and regulatory acceptance considerations for alternative toxicological test methods.
Schechtman LM
ILAR J; 2002; 43 Suppl():S85-94. PubMed ID: 12388858
[TBL] [Abstract][Full Text] [Related]
2. A new path forward: the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).
Casey W; Jacobs A; Maull E; Matheson J; Clarke C; Lowit A
J Am Assoc Lab Anim Sci; 2015 Mar; 54(2):170-3. PubMed ID: 25836963
[TBL] [Abstract][Full Text] [Related]
3. The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): a review of the ICCVAM test method evaluation process and current international collaborations with the European Centre for the Validation of Alternative Methods (ECVAM).
Stokes WS; Schechtman LM; Hill RN
Altern Lab Anim; 2002 Dec; 30 Suppl 2():23-32. PubMed ID: 12513648
[TBL] [Abstract][Full Text] [Related]
4. The FDA's regulatory role in the ICCVAM process.
Schechtman LM; Stokes WS
Altern Lab Anim; 2004 Jun; 32 Suppl 1B():663-8. PubMed ID: 23581155
[TBL] [Abstract][Full Text] [Related]
5. Validation and regulatory acceptance of alternatives.
Hill RN; Stokes WS
Camb Q Healthc Ethics; 1999; 8(1):73-9. PubMed ID: 9924621
[No Abstract] [Full Text] [Related]
6. Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use.
Corvi R; Ahr HJ; Albertini S; Blakey DH; Clerici L; Coecke S; Douglas GR; Gribaldo L; Groten JP; Haase B; Hamernik K; Hartung T; Inoue T; Indans I; Maurici D; Orphanides G; Rembges D; Sansone SA; Snape JR; Toda E; Tong W; van Delft JH; Weis B; Schechtman LM
Environ Health Perspect; 2006 Mar; 114(3):420-9. PubMed ID: 16507466
[TBL] [Abstract][Full Text] [Related]
7. ICCVAM evaluation of the murine local lymph node assay. The ICCVAM review process.
Sailstad DM; Hattan D; Hill RN; Stokes WS
Regul Toxicol Pharmacol; 2001 Dec; 34(3):249-57. PubMed ID: 11754529
[TBL] [Abstract][Full Text] [Related]
8. ECVAM-ICCVAM: prospects for future collaboration.
Schechtman LM; Stokes WS
Altern Lab Anim; 2002 Dec; 30 Suppl 2():227-36. PubMed ID: 12513682
[TBL] [Abstract][Full Text] [Related]
9. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
[TBL] [Abstract][Full Text] [Related]
10. Refinement, reduction, and replacement of animal use for regulatory testing: future improvements and implementation within the regulatory framework.
Richmond J
ILAR J; 2002; 43 Suppl():S63-8. PubMed ID: 12388854
[TBL] [Abstract][Full Text] [Related]
11. Future improvements: replacement in vitro methods.
Balls M
ILAR J; 2002; 43 Suppl():S69-73. PubMed ID: 12388855
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
Beken S; Kasper P; van der Laan JW
Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
[TBL] [Abstract][Full Text] [Related]
13. A critical appraisal of the process of regulatory implementation of novel in vivo and in vitro methods for chemical hazard and risk assessment.
Piersma AH; Ezendam J; Luijten M; Muller JJ; Rorije E; van der Ven LT; van Benthem J
Crit Rev Toxicol; 2014 Nov; 44(10):876-94. PubMed ID: 25058877
[TBL] [Abstract][Full Text] [Related]
14. United States regulatory requirements for skin and eye irritation testing.
Choksi NY; Truax J; Layton A; Matheson J; Mattie D; Varney T; Tao J; Yozzo K; McDougal AJ; Merrill J; Lowther D; Barroso J; Linke B; Casey W; Allen D
Cutan Ocul Toxicol; 2019 Jun; 38(2):141-155. PubMed ID: 30418044
[TBL] [Abstract][Full Text] [Related]
15. Skin sensitization testing needs and data uses by US regulatory and research agencies.
Strickland J; Daniel AB; Allen D; Aguila C; Ahir S; Bancos S; Craig E; Germolec D; Ghosh C; Hudson NL; Jacobs A; Lehmann DM; Matheson J; Reinke EN; Sadrieh N; Vukmanovic S; Kleinstreuer N
Arch Toxicol; 2019 Feb; 93(2):273-291. PubMed ID: 30377734
[TBL] [Abstract][Full Text] [Related]
16. Validating new toxicology tests for regulatory acceptance.
Zeiger E; Stokes WS
Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):32-7. PubMed ID: 9629594
[TBL] [Abstract][Full Text] [Related]
17. Knowledge sharing to facilitate regulatory decision-making in regard to alternatives to animal testing: Report of an EPAA workshop.
Ramirez T; Beken S; Chlebus M; Ellis G; Griesinger C; De Jonghe S; Manou I; Mehling A; Reisinger K; Rossi LH; van Benthem J; van der Laan JW; Weissenhorn R; Sauer UG
Regul Toxicol Pharmacol; 2015 Oct; 73(1):210-26. PubMed ID: 26188116
[TBL] [Abstract][Full Text] [Related]
18. ICH guidelines--implementation of the 3Rs (refinement, reduction, and replacement): incorporating best scientific practices into the regulatory process.
Ohno Y
ILAR J; 2002; 43 Suppl():S95-8. PubMed ID: 12388859
[TBL] [Abstract][Full Text] [Related]
19. The Third FRAME Toxicity Committee: working toward greater implementation of alternatives in toxicity testing.
Combes RD; Balls M; Bansil L; Barratt M; Bell D; Botham P; Broadhead C; Clothier R; George E; Fentem J; Jackson M; Indans I; Loizou G; Navaratnam V; Pentreath V; Phillips B; Stemplewski H; Stewart J
Altern Lab Anim; 2004 Jun; 32 Suppl 1B():635-42. PubMed ID: 23581152
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
